A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs TMX 049 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Teijin
- 19 Sep 2019 Results presented in the XORTX Therapeutics media release.
- 19 Sep 2019 Primary endpoint (Change in log-transformed urinary albumin-to-creatinine ratio (UACR)) has been met, according to the XORTX Therapeutics media release.
- 10 Sep 2019 Status changed from active, no longer recruiting to completed.